SYNAGEVA BIOPHARMA CORP (GEVA) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 422 transactions totaling $691.2M, demonstrating a bullish sentiment with $466.0M in net insider flow. The most recent transaction on Jun 22, 2015 involved a transaction of 55,479 shares valued at $0.
No significant insider buying has been recorded for GEVA in the recent period.
No significant insider selling has been recorded for GEVA in the recent period.
Based on recent SEC filings, insider sentiment for GEVA is bullish with an Insider Alignment Score of 84/100 and a net flow of $466.0M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at SYNAGEVA BIOPHARMA CORP (GEVA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading GEVA stock, having executed 422 transactions in the past 90 days. The most active insider is Felix Baker (Executive), who has made 31 transactions totaling $298.5M.
Get notified when executives and directors at GEVA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 22, 2015 | Baker Felix | Executive | Other | 55,479 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 12,500 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 165,213 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 19,318 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 206,800 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 211,614 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 497 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 100,490 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 40,449 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 1,068,128 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 5,543 | $N/A | $0 | |
| Jun 22, 2015 | Baker Felix | Executive | Other | 21,196 | $N/A | $0 | |
| Jun 22, 2015 | Baker Julian | Executive | Other | 211,614 | $N/A | $0 | |
| Jun 22, 2015 | Baker Julian | Executive | Other | 21,196 | $N/A | $0 | |
| Jun 22, 2015 | Baker Julian | Executive | Other | 206,800 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 23 | $578.6M | 78.3% |
Sale(S) | 174 | $112.6M | 15.2% |
Award(A) | 46 | $32.7M | 4.4% |
Exercise(M) | 131 | $14.7M | 2.0% |
Other(J) | 24 | $0 | 0.0% |
Disposition(D) | 24 | $0 | 0.0% |
Insiders at SYNAGEVA BIOPHARMA CORP are accumulating shares at an accelerated pace. With 19 insiders making 422 transactions totaling $578.6M in purchases versus $112.6M in sales, the net buying activity of $466.0M signals strong executive confidence. Felix Baker (Executive) leads the buying activity with $298.5M in transactions across all time.